Department of Health Policy and Management, Rollins School of Public Health (Emory University), Atlanta, GA 30322, USA.
Malar J. 2013 Jul 11;12:236. doi: 10.1186/1475-2875-12-236.
Anti-malarial regimens containing sulphonamide or artemisinin ingredients are widely used in malaria-endemic countries. However, evidence of the incidence of adverse drug reactions (ADR) to these drugs is limited, especially in Africa, and there is a complete absence of information on the economic burden such ADR place on patients. This study aimed to document ADR incidence and associated household costs in three high malaria transmission districts in rural Tanzania covered by demographic surveillance systems.
Active and passive surveillance methods were used to identify ADR from sulphadoxine-pyrimethamine (SP) and artemisinin (AS) use. ADR were identified by trained clinicians at health facilities (passive surveillance) and through cross-sectional household surveys (active surveillance). Potential cases were followed up at home, where a complete history and physical examination was undertaken, and household cost data collected. Patients were classified as having 'possible' or 'probable' ADR by a physician.
A total of 95 suspected ADR were identified during a two-year period, of which 79 were traced, and 67 reported use of SP and/or AS prior to ADR onset. Thirty-four cases were classified as 'probable' and 33 as 'possible' ADRs. Most (53) cases were associated with SP monotherapy, 13 with the AS/SP combination (available in one of the two areas only), and one with AS monotherapy. Annual ADR incidence per 100,000 exposures was estimated based on 'probable' ADR only at 5.6 for AS/SP in combination, and 25.0 and 11.6 for SP monotherapy. Median ADR treatment costs per episode ranged from US$2.23 for those making a single provider visit to US$146.93 for patients with four visits. Seventy-three per cent of patients used out-of-pocket funds or sold part of their farm harvests to pay for treatment, and 19% borrowed money.
Both passive and active surveillance methods proved feasible methods for anti-malarial ADR surveillance, with active surveillance being an important complement to facility-based surveillance, given the widespread practice of self-medication. Household costs associated with ADR treatment were high and potentially catastrophic. Efforts should be made to both improve pharmacovigilance across Africa and to identify strategies to reduce the economic burden endured by households suffering from ADR.
含有磺胺或青蒿素成分的抗疟方案在疟疾流行国家广泛使用。然而,这些药物不良反应(ADR)发生率的证据有限,特别是在非洲,而且对于这些 ADR 给患者带来的经济负担,完全没有信息。本研究旨在记录在坦桑尼亚农村三个疟疾高传播地区,使用磺胺多辛-乙胺嘧啶(SP)和青蒿素(AS)的 ADR 发生率,并评估其相关家庭成本。
采用主动和被动监测方法,从磺胺多辛-乙胺嘧啶(SP)和青蒿素(AS)的使用中识别 ADR。通过训练有素的临床医生在医疗机构(被动监测)和通过横断面家庭调查(主动监测)来识别 ADR。对疑似病例进行家庭随访,进行完整的病史和体格检查,并收集家庭费用数据。医生将疑似病例分为“可能”和“确定”的 ADR。
在两年期间共发现 95 例疑似 ADR,其中 79 例得到追踪,67 例在 ADR 发生前报告使用 SP 和/或 AS。34 例被分类为“确定”和 33 例为“可能”ADR。大多数(53 例)与 SP 单药治疗有关,13 例与 AS/SP 联合治疗有关(仅在两个地区中的一个地区可用),1 例与 AS 单药治疗有关。基于“确定”的 ADR,每年每 10 万例暴露的 ADR 发生率估计为 AS/SP 联合用药为 5.6,SP 单药治疗为 25.0 和 11.6。每次 ADR 治疗的中位费用从单次就诊的 2.23 美元到 4 次就诊的 146.93 美元不等。73%的患者使用自费资金或出售部分农作物来支付治疗费用,19%的患者借钱。
被动和主动监测方法均被证明是抗疟 ADR 监测的可行方法,主动监测是对医疗机构监测的重要补充,因为自我用药的情况普遍存在。ADR 治疗相关的家庭成本很高,可能会造成灾难性后果。应努力在整个非洲改善药物警戒,并确定减轻遭受 ADR 之苦的家庭经济负担的策略。